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ABSTRACT
The ATPase Inhibitory Factor 1 (IF1) is an inhibitor of the mitochondrial H+-ATP 
synthase that regulates the activity of both oxidative phosphorylation (OXPHOS) 
and cell death. Here, we have developed transgenic Tet-On and Tet-Off mice that 
express a mutant active form of hIF1 in the hepatocytes to restrain OXPHOS in the 
liver to investigate the relevance of mitochondrial activity in hepatocarcinogenesis. 
The expression of hIF1 promotes the inhibition of OXPHOS in both Tet-On and Tet-
Off mouse models and induces a state of metabolic preconditioning guided by the 
activation of the stress kinases AMPK and p38 MAPK. Expression of the transgene 
significantly augmented proliferation and apoptotic resistance of carcinoma cells, 
which contributed to an enhanced diethylnitrosamine-induced liver carcinogenesis. 
Moreover, the expression of hIF1 also diminished acetaminophen-induced 
apoptosis, which is unrelated to differences in permeability transition pore opening. 
Mechanistically, cell survival in hIF1-preconditioned hepatocytes results from a 
nuclear factor-erythroid 2-related factor (Nrf2)-guided antioxidant response. The 
results emphasize in vivo that a metabolic phenotype with a restrained OXPHOS in 
the liver is prone to the development of cancer. 
INTRODUCTION
Mitochondria play key roles in cell metabolism 
and bioenergetics, mediate intracellular signaling by 
calcium and reactive oxygen species (ROS) and regulate 
the execution of cell-death [1]. Most of the ATP that is 
required to maintain cellular activities is synthesized by 
the mitochondrial H+-ATP synthase [2]. Down-regulation 
of oxidative phosphorylation (OXPHOS) and the 
concurrent activation of aerobic glycolysis is a hallmark 
of proliferating cancer cells [1, 3] whereas an increase 
in oxidative metabolism halts cellular proliferation and 
tumor progression [1, 4, 5]. The activity of OXPHOS 
is required for the execution of cell death [1, 6] and in 
particular, the ATP synthase is needed for the execution of 
apoptosis [7] as recently demonstrated in neurons in vivo 
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[8]. In fact, the ATP synthase is a critical component in 
the permeabilization of the inner mitochondrial membrane 
to low molecular weight solutes, i.e., in the opening of 
the permeability transition pore (PTP) [9-11]. Not 
surprisingly, inhibition of the ATP synthase is involved in 
lifespan extension [12, 13] illustrating the relevance of this 
protein complex in aging and age-related diseases. 
In mitochondria, futile ATP hydrolysis by the ATP 
synthase is inhibited by the ATPase Inhibitory Factor 1 
(IF1) a small nuclear-encoded protein that reversibly 
binds to the enzyme [2]. Data obtained in cancer [14, 
15], in stem cells [16], and in a mouse model over-
expressing an active form of IF1 in neurons[8], support 
that in vivo IF1 also inhibits the synthase activity of the 
ATP synthase. The IF1-mediated inhibition of the ATP 
synthase prevents cell death [8, 14, 17]. Remarkably, 
IF1 is highly over-expressed in human carcinomas [14, 
15, 18]. In hepatocarcinomas the over-expression of IF1 
favors angiogenesis and metastasis [19].
Herein, we have questioned: What is the relevance 
of a metabolic phenotype with a restrained OXPHOS in 
cancer onset and progression in vivo? To that aim we have 
generated transgenic mice that express a mutant active 
form of human IF1 (hIF1) under a tetracycline regulated 
promoter in hepatocytes. We show that expression of 
the transgene promotes inhibition of OXPHOS and a 
higher susceptibility to diethyl-nitrosamine (DEN)-
induced carcinogenesis. Mechanistically, an enhanced 
carcinogenesis in hepatocytes of hIF1 expressing mice 
involves an enhanced proliferation and the down-
regulation of the potential to execute cell death as further 
illustrated in vivo in a model of acetaminophen (APAP)-
induced hepatotoxic damage. Cell survival in hIF1 
expressing hepatocytes is not mediated by differential 
regulation of PTP opening in response to APAP treatment 
but by the induction of a nuclear factor-erythroid 2-related 
factor (Nrf2)-guided antioxidant response. These findings 
emphasize that metabolic preconditioning by restraining 
OXPHOS is deleterious in the context of liver cancer 
because it limits cell death favoring the progression of 
oncogenic events. 
RESULTS
In vivo IF1-mediated inhibition of OXPHOS in 
the liver of Tet-Off mice
Breeding of mice expressing the tTA transactivator 
in liver with transgenic mice containing the human IF1-
H49K transgene (hIF1) resulted in double transgenic mice 
(T/H). The double transgenic animals (T/H) expressed 
hIF1 in the absence of Doxycycline (Dox) administration 
as revealed by the presence of hIF1 mRNA and protein 
levels in their livers (Figure 1A). Expression of hIF1 is 
restricted to mitochondria of hepatocytes (Figure 1B) 
and negatively regulated by the administration of Dox 
as revealed by qPCR and western blotting (Figure 1A), 
confocal microscopy (Figure 1B, panels to the left) 
and immunohistochemistry (Figure 1B, panels to the 
right). The expression of hIF1 had no impact on the 
expression level of relevant mitochondrial proteins of 
different OXPHOS complexes (Figure 1C). Isolated liver 
mitochondria from adult T/H mice revealed that both the 
ADP-stimulated respiration and the maximum respiratory 
rates were significantly reduced when compared to 
littermate controls (Figure 1D). In addition, liver ATP 
concentrations were diminished in T/H mice (Figure 1E). 
An overnight fast of adult Tet-Off T/H mice promoted 
a significant reduction in blood glucose and lactate 
concentrations (Figure 1F). 
In vivo IF1-mediated inhibition of OXPHOS in 
the liver of Tet-On mice
Breeding of mice expressing the rtTA-Adv 
transactivator in liver with transgenic mice containing 
the human IF1-H49K transgene (hIF1) (Supplemental 
Figure S1A) resulted in double transgenic mice (T/H) 
(Supplemental Figure S1B) able to express hIF1 in the 
liver only in response to the administration of doxycycline 
(Dox) (Supplemental Figure S1B). The expression level 
of hIF1 varied among different T/H mice (Supplemental 
Figure S1B) and was higher than that of the endogenous 
IF1 present in mouse liver of control littermates 
(Supplemental Figure S1C). Expression of hIF1 was 
preferentially concentrated in perivenous hepatocytes 
(Supplemental Figure S1D) and had no impact on the 
expression level of relevant mitochondrial proteins of 
different OXPHOS complexes (Supplemental Figure S1E). 
T/H mice showed no differences in weight, life span and 
cage behavior when compared to controls after one year of 
follow up. However, and consistent with the inhibitory role 
of IF1 on the activity of the H+-ATP synthase we observed 
that both the basal and the ADP-stimulated respiration 
in isolated mitochondria from adult livers of T/H mice 
was significantly reduced when compared to controls 
(Supplemental Figure S1F). A significant decrease in the 
maximum respiratory rate was also noted in mitochondria 
of T/H mice (Supplemental Figure S1F). Overall, these 
findings indicate that expression of hIF1 is partially 
arresting both respiration and ADP phosphorylation in 
liver mitochondria. 
In agreement with a partial energy deficit in the 
liver of T/H mice we observed: (i) reduced ATP and 
increased AMP contents in their livers (Supplemental 
Figure S2A), (ii) a significant increase in the AMP/ATP 
ratio (Supplemental Figure S2A) and (iii) the activation 
by phosphorylation of the metabolic stress kinase AMPK 
(Supplemental Figure S2B), when compared to liver 
of controls. The pyruvate content was also diminished 
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in the liver of T/H mice (Supplemental Figure S2C). 
Other liver organic acids showed no relevant differences 
(Supplemental Figure S2C). Blood glucose and 
lactate concentrations were not significantly different 
between fed T/H and control mice (Supplemental 
Figure S2D). However, an overnight fast promoted a 
marked hypoglycaemia (Supplemental Figure S2E) and 
hypolactatemia (Supplemental Figure S2E) in T/H mice. 
The liver of 15 day-old T/H neonates revealed a significant 
induction of mitochondrial superoxide dismutase (SOD2) 
(Supplemental Figure S2F). Functionally, induction 
of SOD2 in liver of T/H mice was expressed by less 
carbonylation of some cellular proteins when compared to 
livers of control mice (Supplemental Figure S2G). These 
results suggest that a limited OXPHOS by the expression 
of hIF1 in the liver of T/H mice compromises the energy 
supply needed for normal activity of gluconeogenesis and 
eventually favors the utilization of lactate for oxidative 
purposes in extrahepatic tissues during fasting. Overall, 
using two different experimental systems to regulate 
the expression of hIF1 in mouse liver we show that its 
expression triggers an energy deficit in the hepatocytes 
by inhibiting the activity of OXPHOS. Dox is known 
to induce the arrest of mitochondrial protein translation 
[20, 21], and eventually, to promote the unfolded protein 
response in mitochondria (UPRmt) [22]. Since we 
obtained similar findings with a Tef-Off mouse model 
(Figure 1), we ruled out any role for Dox in triggering 
metabolic adaptation by unleashing the UPRmt.
Figure 1: OXPHOS is inhibited in the liver of mice expressing hIF1. Only the double transgenic animals (T/H) expressed hIF1 
in the absence of Doxycycline (Dox) administration. A. hIF1 mRNA expression in the liver of control (CRL) and T/H mice. Blot of hIF1 
(12 kDa) and β-F1-ATPase (β-F1) in T/H and CRL mice. B. Double-immunofluorescence microscopy (63X) of liver from CRL and T/H 
mice stained with IF1 (green) and β-F1-ATPase (red) antibodies. Merged images (IF1+β-F1). Immunohistochemistry for hIF1 in the liver 
of T/H mice at 20X and 63X magnification. C. Blots of hIF1, complex I (NADH s9), complex II (SDH-B), complex III (Core2), complex 
IV (COXI and COX IV) and complex V (β-F1), Hsp60 and GAPDH in liver extracts of CRL and T/H mice. Histograms to the right show 
the relative expression of each protein normalized to GAPDH expression. D. Polarographic determination of basal, ADP-stimulated and 
FCCP-stimulated respiration in isolated liver mitochondria of CRL and T/H mice. The results are the mean ± SEM of 8 mice per group. E. 
ATP concentration in liver extracts of CRL and T/H mice. The results shown are the mean ± SEM of 5 mice per group. F. Blood glucose 
and lactate concentrations of fasted CRL and T/H mice. Histograms are the mean ± SEM of 12-14 mice per group. (C-F) *, p < 0.05 when 
compared to control by Student’s t test. See also Figures S1 and S2.
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Expression of hIF1 affects the activity and 
assembly of Complex IV and Complex V
Isolated liver mitochondria from both the hIF1 
expressing Tet-On and Tet-Off mice revealed reduced 
activities of Complex IV and V when compared to controls 
(Figure 2A). In contrast, the activities of Complex I and 
II+III were not significantly affected by the expression of 
hIF1 (Figure 2A). Interestingly, a significant correlation 
between the inhibition of Complex V and Complex IV 
activities was observed (Figure 2A). In-gel activity of 
complexes I and IV revealed that whereas the activity 
of Complex I was not modified in hIF1 expressing Tet-
Off mice, the activity of Complex IV and its super-
complexes were very much reduced (Figure 2B). A 
similar study to assess the oligomycin (OL)-sensitive 
ATP hydrolase activity in super-complexes confirmed that 
hIF1 expressing mice had reduced ATPase activity despite 
essentially containing the same amount of the β-catalytic 
subunit of the complex in ATPase oligomers (Figure 2C). 
Western blotting of BN-gels appears to confirm that 
the assembly of Complex IV was reduced in both mouse 
models of hIF1 expressing mice because its monomeric 
form was diminished when compared to that of controls 
(Figure 2D), what is in agreement with the reduced 
Complex IV activity observed in these animals (Figure 
2A, 2B). Likewise, the expression of hIF1 in the liver of 
both Tet-On and Tet-Off mice promoted the assembly of 
a low migrating super-complex that contained complex V 
and might represent dimers of the ATP synthase ((CV)2 
in Figure 2D). Trypsin digestion and mass spectrometric 
analysis of the three upper bands recognized by anti-β-
F1-ATPase antibody supported these results and revealed 
that the major component of the SC band in Figure 2D is 
Complex I (see Supplemental Table SI).
Figure 2: Activities and assembly of OXPHOS complexes in the liver of hIF1 mice. A. Enzymatic activities of complex I, 
II+III, IV and V in isolated liver mitochondria of CRL and T/H mice. Histograms are the mean ± SEM of 3 experiments. *, p<0.05 when 
compared to control by Student’s t test. Linear correlation between the inhibition of Complex V activity by hIF1 and the inhibition of 
Complex IV activity. B. BN-PAGE-in-gel-activities of Complex I and Complex IV (low and high exposures). C. CN-PAGE immunoblot 
analysis of β-F1-ATPase (βF1) and CN-PAGE-in-gel-activity of complex V in the presence (+) or absence (-) of oligomycin (OL). D. BN-
PAGE immunoblot analysis of mitochondrial complexes IV (COX IV) and V (β-F1-ATPase). The migration of dimers of ATP synthase 
(CV)2, supercomplex (SC), ATP synthase (FoF1), F1-ATPase (F1) and complex IV (C IV) is indicated. See also Supplemental Table S1.
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A diminished activity of OXPHOS favors 
hepatocarcinogenesis
A preliminary experiment of DEN-induced 
hepatocarcinogenesis by single injection of DEN [23] was 
initially done in a small number of mice (Supplemental 
Figure S3). Hepatocarcinogenesis was further studied 
with the long-term DEN administration protocol [24] 
(Figure 3) because it leads to a higher tumor incidence 
in a shorter time span [25]. Both protocols provided the 
same findings (Figure 3 and Supplemental Figure S3). 
Dox administration slightly reduced the body weight of 
the animals (Figure 3A). In contrast, the liver weight of 
DEN-treated mice and especially of those expressing 
hIF1 was significantly augmented when compared to 
the rest of the animals (T/H minus Dox in Figure 3B). 
The increase in liver weight of mice expressing hIF1 was 
accompanied by a significant progressive increase in blood 
glutamate-pyruvate transaminase (GPT) activity towards 
the end of the study (Figure 3C and see Supplemental 
Figures  S3C and S4). Consistent with these observations 
both the number of tumors and total tumor volume were 
significantly increased in hIF1 expressing mice (Figure 
3D). Dox administration reduced the number of tumors 
and total tumor volume both in control and hIF1 silenced 
T/H mice (Figure 3D). The higher tumor burden of mice 
expressing the transgene resulted from increased rates of 
proliferation (Figure 4A) and diminished apoptosis (Figure 
4B, 4C) as assessed by immunohistochemical analysis of 
the carcinomas. Overall, these findings indicate in vivo 
the oncogenic role of IF1 and that limiting the activity of 
OXPHOS in the liver favors cancer onset and progression.
The mitochondrial phenotype in 
hepatocarcinogenesis
Immunohistochemical, electron microscopy and 
molecular analysis of the livers revealed that long-term 
DEN-induced hepatocarcinogenesis in mice largely 
reproduced the findings on the mitochondrial phenotype 
previously reported in human hepatocarcinomas [26]. 
In fact, it was observed that tumor areas in both T/H 
Figure 3: The expression of hIF1 increased DEN-induced hepatocarcinogenesis (HCC). A.-C. Changes in body weight (A), 
liver weight (B) and blood GPT (C) in PBS or DEN-treated CRL (open bars) and hIF1 Tet-Off T/H (closed bars) mice, treated in presence 
(+) or absence (-) of Dox. D. CRL and T/H livers of mice treated (+) or not treated (-) with DEN. The effect of Dox administration (+) or 
not (-) is also shown. The number of tumors and the total tumor volume in DEN-treated CRL (open bars) and T/H (closed bars) mouse 
livers treated (+) or not (-) with Dox. The number of mice is indicated in parenthesis. Results are means ± SEM. P values by Student’s t 
test are indicated. 
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(Figure 5A) and CRL (Supplemental Figure S5A) were 
largely devoid of immunostaining for mitochondrial 
proteins such as β-F1-ATPase, Hsp60 and IF1, suggesting 
that progression of liver cancer is concurrent with 
the repression of mitochondrial biogenesis [26]. We 
observed no relevant differences in the expression of 
the glycolytic markers GAPDH and LDHA as assessed 
by inmmunohistochemical (IHC) (Figure 5A and 
Supplemental Figure S5A). However, since IHC is a 
qualitative technique we assessed protein expression 
by western blotting normal and tumor tissue of CRL 
and T/H mice (Supplemental Figure S5B). The results 
obtained indicate that carcinogenesis promoted the down-
regulation of β-F1-ATPase expression concurrently 
with the upregulation of GAPDH in the absence of 
relevant changes in the expression of Hsp60 and LDHA 
(Supplemental Figure S5C). As a result the bioenergetic 
signature of the tumors, as assessed by the β-F1-ATPase/
GAPDH ratio [26, 27] was significantly diminished when 
compared to the signature in normal tissues (Supplemental 
Figure S5C). Overall, we should mention that we did not 
observe differences in protein expression in the analysis 
of focal hepatic lesions between control and transgenic 
animals (Figure 5A and Supplemental Figure S5A). 
Determination of mtDNA content in T/H mice 
revealed a very large reduction of mtDNA in liver 
tumors when compared to the normal tissue of the same 
liver (Figure 5B). This finding was further confirmed 
by assessing the lower cellular content and alteration of 
mitochondrial structure in these carcinomas by electron 
microscopy (Figure 5C), confirming the repression of 
mitochondrial biogenesis in hepatocarcinogenesis [26]. 
Consistent with the above findings, the expression of the 
transcriptional co-activator required in mitochondrial 
biogenesis PGC1α was significantly reduced in mouse 
carcinomas when compared to normal liver samples 
(Figure 5D).
Moreover, since DEN-induced hepatocarcinogenesis 
is an example of inflammation-driven tumorigenesis 
we also analyzed macrophage recruitment to focal 
hepatic lesions in CRL and T/H mice using the F4/80 
antibody. The results reveal that there are no differences 
in macrophage recruitment to the tumor areas between 
control and T/H mice (Supplemental Figure S6).
Limiting OXPHOS minimizes apoptotic cell-death
To provide further mechanistic insight into the 
main pathway that might participate in the hIF1-mediated 
stimulation of liver cancer we studied the cell-death 
response of control and T/H mice to liver induced injury by 
APAP [28]. APAP overdose promoted a clear centrilobular 
hepatic cell death at 8h post-administration that was more 
evident in livers of control than of T/H mice (Figure 
6A). Analysis of cell death by terminal deoxynucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) 
(Figure 6B) and active caspase 3 (Figure 6C) revealed that 
Figure 4: Expression of hIF1 promotes increased proliferation and apoptotic resistance of HCC. A.-C. Liver sections 
of DEN-treated CRL and hIF1 Tet-Off T/H mice were processed for immunohistochemistry to assess the rates of proliferation (A, Ki-67 
staining) and apoptosis (B, phospho-p53 and C, TUNEL) in HCC. Magnification 5x-10x. Bars are the mean ± SEM of 6 mice per group. *, 
p<0.05 when compared to CRL by Student’s t test.
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Figure 5: Repression of mitochondrial biogenesis in DEN-induced hepatocarcinogenesis (HCC). A. Focal hepatic lesions 
(magnification 5x) in long-term DEN-treated T/H mice identified by hematoxylin-eosin (H&E) and immunohistochemical staining with 
the antibodies against β-F1-ATPase (β-F1); Hsp60; hIF1; GAPDH and LDHA in the same localized tumor area (panels to the left). The 
same study in normal (N, upper left) and tumor (T, lower right) areas at 20X magnification (panels to the right). A dashed line marks 
the border between tumor and non-tumor areas. B. mtDNA copy number in DNA extracted from normal (N) and tumor (T) liver tissue 
of hIF1 expressing T/H mice. Results are means ± SEM for 6-7 animals. *P < 0.05 when compared with normal by Student’s t test. C. 
Representative electron micrographs of normal (N) and tumor (T) tissue of the liver of hIF1 expressing T/H mice. Mitochondria of the 
hepatocytes in normal liver showed its characteristic high electron density and inner membrane cristae (left panels), whereas mitochondria 
are barely identifiable in the tumor tissue (right panels). Scale bars: 2k (upper panels); 20k (lower panels). Histograms show the number 
of mitochondria / cell section in normal (N) and tumor (T) tissue in T/H mice. Results are means ± SEM of five different sections from 3 
animals. *P < 0.05 when compared with normal by Student’s t test. D. Cellular mRNA expression of PGC1α in normal (N) and tumor (T) 
tissue of hIF1 expressing T/H mice. Results are means ± SEM of 6 experiments.*, P < 0.05 when compared with normal by Student’s t test. 
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APAP promoted a higher increase in cell death in control 
than in T/H mice, strongly supporting that mice with a 
limited OXPHOS are partially protected from apoptotic 
cell death. Consistent with previous findings regarding 
the lower carbonylation observed in liver proteins of T/H 
mice in the Tet-On model (Supplemental Figure S2G), we 
noted that the oxidation of liver proteins both under basal 
conditions and in response to APAP treatment was less 
pronounced in adult Tet-Off T/H mice (Figure 6D). 
The PTP is not involved in protection against 
death
Findings in different experimental settings support 
the role of OXPHOS [1, 6, 29] and of the H+-ATP synthase 
[7, 30] in cell death. Moreover, it has been reported that 
the PTP is formed by the H+-ATP synthase itself [9-11, 
31, 32]. To verify the putative implication of the PTP 
Figure 6: Restraining OXPHOS protects from APAP-induced cell death. Control (CRL) and hIF1 (T/H) mice were i.p. injected 
with APAP (+) or saline (-). Hematoxylin-eosin A., TUNEL B. and active caspase 3 C. staining in liver sections. Magnification 20x. Bars 
are the mean ± SEM of 6 mice per group. (B,C) *, p<0.05 when compared to non-treated (-) and #, p<0.05 when compared to CRL-APAP 
treated by Student’s t test. D. Carbonylation of liver proteins from CRL and hIF1 (T/H) mice treated (+) or non-treated (-) with APAP 
is shown. The derivation of samples in the presence (+) or absence (-) of DNPH was used for the identification of protein carbonyls. 
Arrowheads (to the right) identify the migration of the three proteins used in quantification (histograms) of protein carbonylation. The 
results shown are the mean ± SEM of six CRL and eight T/H mice, respectively. *, p < 0.05 when compared to non-treated (-) and #, p < 
0.05 when compared to CRL-APAP treated by Student’s t test. 
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in the differential response to cell death between both 
mice phenotypes we studied the Ca2+-retention capacity 
(Figure 7A-7C) and Ca2+-induced swelling (Figure 7D-
7F) of isolated mitochondria from livers of control and 
hIF1 expressing mice. No relevant differences were 
observed in any of these parameters between mitochondria 
of control and T/H mice (Figure 7A & 7D). Moreover, 
both cyclosporine A (CsA) (Figure 7B & 7E) and ATP-
Mg (Figure 7C & 7F), which are known inhibitors of 
PTP opening [9], exerted the same regulation of the PTP 
in control and T/H mice. These findings support that 
inhibition of cell death by IF1 [8, 14, 17] is unrelated 
with PTP opening. Dimers of the ATP synthase have 
been shown to be required for PTP formation [11, 32]. 
Moreover, it has been suggested that IF1 regulates the 
oligomeric state of the ATP synthase increasing the 
formation of dimeric ATP synthase complexes and cristae 
density [33, 34]. Our observation that the expression of 
Figure 7: PTP opening and regulation is not affected by hIF1. A.-C. Calcium green 5N fluorescence in isolated liver mitochondria 
from control (blue traces) and hIF1 Tet-Off expressing (red traces) mice. Representative experiments show no differences between the 
calcium retention capacity of liver mitochondria from CRL and T/H mice after the addition of 10µM Ca2+ (arrows) in the absence (A) or 
presence of the PTP blockers 5 µM CsA (B) or 1mM ATP-Mg2+ (C). D.-F. Representative experiments show no differences in Ca2+ induced 
swelling between liver mitochondria derived from CRL and hIF1 expressing T/H mice after the addition of successive 100µM Ca2+ (arrows) 
except the last one which is 500µM Ca2+ in the absence (D) or presence of 5 µM CsA (E) or 1mM ATP-Mg2+ (F).
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hIF1 in the liver of both the Tet-On and Tet-Off mice 
enhances the assembly of a Complex V super-complex 
(a putative ATPase dimer) is compatible with a role for 
IF1 in promoting the dimeric state of the ATP synthase 
in vivo, although in this situation, the IF1-mediated 
dimerization of the ATP synthase would argue against a 
role for dimeric ATP synthase as a major element of the 
PTP [11, 32]. However, we cannot exclude that additional 
mechanisms that are known to regulate the PTP [9] and 
the ATP synthase [12, 35, 36] could further participate in 
the hIF1-mediated inhibition of cell death. In any case, 
what is evident is that inhibition of the H+-ATP synthase 
mediated either by oligomycin (OL) treatment [7] or by 
hIF1 expression [8, 14] protects from cell death, further 
supporting that the activity of the engine of OXPHOS is 
part of the machinery required for the execution of cell 
death in vivo. 
hIF1 expressing mice are protected against 
oxidative stress
In livers of both mouse phenotypes, GSH levels 
(Figure 8A) and the basal expression of cytochrome P450 
(Cyp2e1) (Figure 8B), both the catalytic and the modifier 
subunits of γ-glutamyl cysteine ligase (GCL-C and 
GCL-M) (Figure 8B) and basal glutathione reductase (GR) 
levels (Figure 8B) were comparable. APAP administration 
decreased both GCL-C and GCL-M (Figure 8B) and 
partially depleted GSH (Figure 8A) at 8 h, these effects 
being significantly ameliorated in T/H mice (Figure 8B 
and Figure 8A, respectively). Moreover, the induction 
of the detoxifying enzyme glutathione reductase (GR) in 
response to APAP challenge was more pronounced in hIF1 
expressing mice (Figure 8B).
 As intracellular redox state is chiefly regulated by 
the transcription factor Nrf2, we examined the expression 
level of total Nrf2. Although no differences were found 
at the basal state (Figure 8C), APAP administration 
significantly increased total Nrf2 degradation in wild-
type mice whereas it was preserved in livers from T/H 
mice (Figure 8C). Likewise, the induction of Nrf2 target 
genes hemoxigenase-1 (HO-1) and superoxide dismutase 
2 (SOD2) in response to APAP was significantly higher 
in mice expressing hIF1 (Figure 8D), consistent with the 
lower oxidative damage of liver proteins found in these 
animals (Figure 6D). Furthermore, we investigated the 
expression of Nrf2 and of redox-related genes (GCL-C, 
GCL-M, GR and SOD2) in normal and tumor tissue of 
control and T/H mice (Supplemental Figure S7). The 
results obtained reveal that tumors from T/H mice have 
higher expression of Nrf2, γ-glutamyl cysteine ligase 
(GCL-M) and mitochondrial superoxide dismutase 
(SOD2) than tumors originated in control animals further 
supporting a role for hIF1in counteracting an Nrf2-guided 
stress response. 
It has been demonstrated that CO, the product 
of HO-1, is able to inhibit tumor necrosis factor alpha 
(TNFα)–induced apoptosis in endothelial cells through 
the activation of p38 MAPK [37]. In light of the low 
HO-1 induction upon APAP injection in wild-type 
mice, phosphorylated p38 MAPK was barely detected 
in these animals (Figure 9A). By contrast, the basal 
phosphorylated p38 MAPK was significantly increased in 
livers of T/H mice (Figure 9A), reinforcing the metabolic 
stress of the hepatocytes in hIF1 expressing mice (Figure 
1 and Supplemental Figures S1 and S2). Moreover, and 
in contrast with wild type mice, T/H mice maintained 
phosphorylated p38 MAPK 8h after APAP injection 
(Figure 9A). The expression and phosphorylation of 
other stress kinases such as JNK and ERK 1/2 was 
not significantly different between control and T/H 
mice (Figure 9A). No differences were also found in 
survival signaling pathways mediated by IRS1/Akt 
between control and hIF1 expressing mice (Figure 9A). 
Remarkably, APAP-treated hIF1-expressing mice showed 
almost complete degradation of the NFκB repressor IκBα 
when compared to control treated mice (Figure 9A), 
supporting also the activation of this survival pathway 
[38]. Consistently, the anti-apoptotic Bcl-xL protein was 
increased at 8h post-APAP injection exclusively in T/H 
mice (Figure 9A). 
DISCUSSION
Herein, we demonstrate in vivo that the expression 
of an active mutant of hIF1 in hepatocytes partially inhibits 
OXPHOS. The inhibition of OXPHOS results in a partial 
energy deficit in the liver, the activation of the metabolic 
stress kinase AMPK and a limited gluconeogenesis after a 
mild overnight fast of the animals. Inhibition of OXPHOS 
by hIF1 is exerted both by limiting the respiratory rate at 
the level of Complex IV and by inhibiting the activity of 
the ATP synthase. The inhibition of the activities of these 
complexes correlated with alterations in both the assembly 
and activities of super-complexes [39]. Within this 
background, a hIF1-limited activity of OXPHOS in the 
liver predisposes to cancer progression. Mechanistically, 
it appears that an enhanced cancer progression in hIF1-
expressing mice is related to its pro-oncogenic activity 
that favors an increased proliferation and an increased 
resistance to execute apoptosis by the hepatocarcinomas. 
Inhibition of cell death seems to be unrelated to hIF1-
mediated differences in PTP opening. Moreover, it appears 
that a restrained OXPHOS switches on a stress response 
that is most likely mediated by the cellular energy and 
redox states of the liver that triggers the basal activation 
of AMPK and p38 MAPK. This is particularly evident 
when the animals are challenged by an APAP overdose 
that induces a strong redox Nrf2 mediated response that 
involves the activation of the NFκB pathway and the 
overexpression of Bcl-xL favoring cell survival. It is 
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Figure 8: APAP treatment triggers a strong antioxidant response in the liver of hIF1 mice. Control (CRL) and Tet-Off (T/H) 
mice were treated (+) or not (-) with APAP. The results shown are the mean ± S.E.M of 6 mice per group. A. Liver GSH content. B.-D. Blots 
of Cyp2e1, GCL-C, GCL-M, GR, Nrf2, HO-1, SOD2 and P85 (used as loading control) in mice treated or not with APAP. Histograms show 
the quantification of the proteins normalized to p85 expression (arbitrary units, a.u.). *, p < 0.05 when compared to CRL non-treated (-) by 
Student’s t test. #, p < 0.05 when compared to CRL-APAP treated by Student’s t test. 
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Figure 9: Signaling pathway in hIF1 expressing mice. Control (CRL) and Tet-Off (T/H) mice were treated (+) or not (-) with 
APAP. The results shown are the mean ± S.E.M of 6 mice per group. A. Blots of the serine-threonine protein kinases: pP38 MAPK / P38 
MAPK; pJNK / JNK; pERK1/2 / ERK 1/2 and pAKT / AKT. Expression of the NFκB inhibitor IκBα, and Bcl-xL in livers is also shown. 
P85 is shown as loading control. Histograms show the quantification of the proteins normalized to p85 expression (arbitrary units, a.u.). *, p 
< 0.05 when compared to CRL non-treated (-); #, p < 0.05 when compared to CRL-APAP treated (+) and +, p < 0.05 when compared to T/H 
non-treated (-) by Student’s t test. B. The bad and the good of mitochondrial ROS. Inhibition of OXPHOS could trigger a rise in the levels 
of ROS. Mild ROS levels (good, in blue) signal metabolic preconditioning and the activation of defenses (mitohormesis) [59] that result 
in cell survival. On the contrary, high ROS levels (bad, in red) cause intracellular damage, genetic alterations and progression to disease. 
Mitohormesis is beneficial for certain type of stressing stimuli, but it can be detrimental in the case of mutagenic events that lead to cancer.
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within this metabolic background when genetic alterations 
that lead to carcinogenesis are able to progress because of 
a limited capacity to execute cell death by mitochondrial 
activity (Figure 9B), in agreement with recent suggestions 
[5] and the clinical observations that cancer recurrence is 
linked to the bioenergetic dysfunction of mitochondria (for 
review [1]). 
Recent findings in in vivo mouse models indicate 
that the activation of mitochondrial OXPHOS provides 
a tumor-suppressive metabolic state [5, 40]. However, 
the role of the partial suppression of OXPHOS in cancer 
onset and progression has not been addressed so far. The 
availability of the Tet-Off T/H mice afforded a unique 
opportunity to verify in vivo the role of OXPHOS in 
carcinogenesis. Although T/H mice do not develop 
spontaneous tumors after more than one year follow up, 
perhaps because they overexpressed p38 MAPK which is 
a known tumor suppressor in the liver [41], they generated 
a three-fold higher number of carcinomas than control 
mice when exposed to DEN, supporting an oncogenic 
role for IF1 and a tumor-suppressive role for an enhanced 
activity of OXPHOS in the liver. 
We have previously suggested a role for IF1 in 
carcinogenesis [14, 18]. Recent findings have stressed that 
a high expression level of IF1 is a bad predictor of survival 
and recurrence of the disease in liver, bladder and gastric 
cancer patients [19, 42, 43]. Moreover, IF1 promotes 
tumorigenesis and metastasis of human hepatocarcinomas 
and gastric cancer cells as assayed in mouse xenografts 
[19, 42]. In liver cancer, IF1 propitiates metastasis and 
angiogenesis through non-canonical signaling of the NFκB 
pathway to Snai1, which mediates epithelial mesenchymal 
transition, and to VEGF, that induces angiogenesis [19]. 
In bladder cancer, the oncogenic role of IF1 seems to be 
dependent on the stimulation of proliferation by cyclins 
and cyclin-dependent kinases related to the G1/S transition 
of the cell cycle [43]. In gastric cancer [42], similarly to 
what we observed in colon cancer [14], the oncogenic 
role of IF1 implicates an enhanced proliferation and 
cell-death resistant phenotype. Cell death resistance in 
colon and lung cancer is mediated by ROS-signaling to 
the canonical NFκB pathway [14, 18], whereas in breast 
and ovarian cancer the mechanism linking IF1 to the cell-
death resistant phenotype remains to be investigated [18]. 
Hence, our findings in the Tet-Off T/H mice provide the 
first in vivo demonstration for the oncogenic role of IF1 
that results from an enhanced proliferation and cell-death 
resistant phenotype of the hepatocyte, the latter attained 
by metabolic pre-conditioning of the anti-oxidant response 
of the liver. 
It should be noted that carcinogenesis differentially 
affects the expression of IF1 in a tissue specific 
manner [18]. Moreover, the overexpression of IF1in 
the carcinomas not always correlate with a bad patient 
prognosis [19, 42, 43]. In fact, the overexpression of IF1 
in breast and colon cancer predicts much better patient’s 
prognosis [18]. These differences might stem from the 
different metabolic traits of the normal tissues as reveal 
by the large tissue-specific differences in the expression 
of IF1, which is very high in liver, kidney and stomach 
and almost negligible in breast, colon and lung [18]. At 
present time, we do not have a mechanistic explanation for 
the apparent tissue-specific differences in the oncogenic 
behavior of IF1. We speculate that mechanisms that 
involve a differential susceptibility of the different cell 
types to particular forms of stress and/or recognition by the 
immune system could be at the bases of these differences. 
Interestingly, Dox administration that is used to 
silence the hIF1 transgene, and is also known to inhibit 
the growth of different cancer cells [20], promoted 
significant reductions in DEN-induced carcinogenesis both 
in the livers of control and hIF1 expressing mice, strongly 
supporting the use of this antibiotic as an anticancer 
agent [44, 45] and further emphasizing that targeting 
mitochondria translation offers an additional strategy to 
combat the disease. 
Chronic liver injury is a major risk factor for the 
development of hepatocellular carcinomas. Interestingly, 
it has been recently demonstrated that dysfunction of 
mitochondrial oxidative phosphorylation ensues during 
the early stages of cirrhosis propitiating an enhanced rate 
of glycolysis [46] which is the metabolic pathway that 
chiefly provides the metabolic precursors that sustain 
proliferation of carcinomas [1]. In agreement with the role 
played by IF1 as inhibitor of OXPHOS and stimulator of 
both glycolysis [15, 18] and proliferation of cancer cells 
[14, 18, 19] we have observed that hIF1 expression in the 
liver mediates the rewiring of metabolism to an enhanced 
glycolysis that could support the elevated proliferation rate 
of the carcinomas. Moreover, the enhanced carcinogenesis 
observed in the liver of hIF1 expressing mice is also 
contributed by the reduced apoptosis observed in these 
tumors. Inhibition of the H+-ATP synthase by hIF1 is 
known to generate a mild ROS signal that induces NFκB-
guided nuclear programs of cell death evasion [8, 14, 
18] and activate epithelial-mesenchymal transitions that 
favors metastasis [19]. This redox condition of the liver 
is consistent with the pathophysiological context for the 
development of hepatocellular carcinomas. Indeed, it has 
been previously suggested that increased intracellular 
ROS in chronic inflammatory states of the liver protect 
against cell death [47] and the increased basal ROS 
levels of cirrhotic hepatocytes seem to determine its 
increased apoptosis resistance [48]. Altogether, these 
findings reinforce the crucial role played by mitochondrial 
dysfunction during tumor transformation and suggest that 
the inhibition of the H+-ATP synthase could represent a 
primary event in hepatic injury leading to the onset of 
carcinomas. 
Energy limitation by a restrained activity of 
OXPHOS is known to induce the metabolic stress kinase 
AMPK [49] and to generate a mitochondrial ROS signal 
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of mild intensity [14]. This signal could also contribute to 
the induction of AMPK and of the stress p38 MAP kinase 
since it could modify the reduction state of thioredoxin 
which is known to halt the activation of both AMPK [50] 
and p38 MAPK [51]. The redox-mediated preconditioning 
is manifested when the animals are challenged with a 
ROS stressor such as APAP. Hence, we support that ROS-
mediated signaling [8, 14] is the primary mechanism 
involved in evasion of cell-death mediated by IF1 in the 
liver. Indeed, the maintenance of total Nrf2 expression 
in the liver of T/H mice orchestrates a stress response 
that involves the overexpression of SOD2 and HO-1 
as well as the detoxification of oxidized glutathione to 
provide protection against oxidative stress and cell death. 
Metabolic preconditioning and protection against death 
seems to be exerted by the basal activation of p38 MAPK 
and AMPK because other stress kinases such as JNK, 
ERK1/2 and Akt are not modified by the overexpression of 
hIF1 in the liver. The transcription factor NFκB is a crucial 
regulator of cell survival pathways [52]. The degradation 
of IKBα, which is the repressor of the NFκB pathway, 
and the concurrent accumulation of the anti-apoptotic 
Bcl-xL in the liver of T/H mice once again highlight the 
crosstalk between ROS and NFκB, and further implicate 
this pathway in hIF1-mediated cell survival after APAP 
treatment. Moreover, the transcriptional crosstalk between 
IF1 and the NFκB pathway has also been recently 
implicated in other hallmarks of liver cancer such as 
promoting angiogenesis and metastasis [19]. We cannot 
exclude that the maintenance of the phosphorylated state 
of p38 MAPK after APAP-induced cell death in T/H 
mice could contribute to cell survival because it has been 
shown to suppress ROS accumulation and cell death in 
hepatocytes [41]. Moreover, the activation of p38 MAPK 
has been reported to inhibit TNFα-induced apoptosis 
in endothelial cells [37]. In any case, the activation of 
different signaling pathways upon OXPHOS-mediated 
tissue preconditioning, p38 MAPK in the liver (this study) 
and PI3K/Akt in neurons [8], supports a large cell-type 
variability in mitochondrial signaling responses. 
Overall, our data provide the first in vivo 
demonstration that the partial inhibition of OXPHOS 
generates a metabolic phenotype that is more prone to 
the development of cancer (Figure 9B), further indicating 
the pro-oncogenic nature of IF1. Hence, we conclude that 
the bioenergetic activity of mitochondria acts as a tumor-
suppressor and guardian of cancer onset and progression. 
MATERIALS AND METHODS 
Transgenic animals
Transgenic mice containing the mutant H49K 
version of hIF1 (TRE-H49K-25, H) were obtained 
by pronuclear microinjection [8]. The commercially 
available B6.Cg-Tg(Lap-tTA)5Bjd/J mice (T) and 
B6.Cg-Tg(Cewbpb-rtTA2S*S2)1Bjd/Ibcm mice (rT), 
expressing respectively the transactivators tTA or rtTA 
in hepatocytes were used. The Tet-Off and Tet-On (T/H) 
double transgenic animals were obtained. To express hIF1, 
double transgenic T/H mice were administered (Tet-On) 
or not (Tet-Off) Dox (2mg/mL) in the drinking water. 
Animal experiments were carried out after approval of the 
Institutional Review Board (CEI-52-961) in compliance 
with animal policies and ethical guidelines of the 
European Community. 
Determination of blood and liver metabolites
Adenine nucleotides and other liver metabolites 
were extracted from frozen liver powder with a 6% 
perchloric acid. The ATP concentration was determined 
using the ATP Bioluminescence Assay Kit CLS II (Roche). 
Liver GSH and GSSG concentrations were determined 
using the Glutathione Assay Kit (BioVision Inc.). 
Western blotting, antibodies and protein 
carbonylation
The primary monoclonal antibodies developed in 
our lab and used in this study were: HSP60 (1:5,000), 
anti-NADH-9 (1:1,000), anti-β-F1-ATPase (1:20,000), 
anti-LDH-A (1:1,000) and anti-GAPDH (1:20,000) [53, 
54]. The monoclonal antibody specifically recognizing 
the human [15] and mouse (Molecular Probes) IF1 
proteins were used at 1:200 dilution. Other antibodies 
used were: anti-SDH-B (1:1000) from Life Technologies; 
anti-Complex III subunit Core 2 (1:1,000), anti-COXI 
(1:1,000), anti-COXIV (1:1,000) and anti-Cyp2e1 
antibody (aB19140) from Abcam; anti-SOD2 (1:5,000), 
anti-JNK (sc-571; 1:1000), anti-phospho-Akt (Ser473) 
(sc-7985-R; 1:1000), anti-phospho-Akt (Thr308) (sc-
16646-R; 1:1000) and anti-Nrf2 (C-20), (sc-722; 1:1000) 
from Santa Cruz Biotechnology, Inc.; anti-Bclx (610211; 
1:1000) antibody from BD Biosciences; anti-IκBα 
(1:1,000), anti-phospho JNK (Thr183/Tyr185) (#4668, 
1:1000), anti-phospho p38 MAPK (Thr180/Tyr182) 
(#9211; 1:1000), anti-p38 MAPK (#9212; 1:1000), anti-
Phospho-p53(Ser15) (1:400) and anti-Akt (#9272; 1:1000) 
antibodies from Cell Signaling Technology Inc; anti-IRS1 
(06-248; 1:1000), anti-p85 (06-195; 1:1000) and anti-HO1 
(AB1284; 1:1000) antibodies from Upstate (Millipore); 
Anti-Ki-67 (SP6) (RM-9106-S1 1:200) from Fischer 
Scientific; Anti-F4/80 (123101; 1:200) from BioLegend; 
Anti-GCLc and GCLm antibodies were a gift from T 
Kavanagh (University of Washington, USA). Peroxidase-
conjugated anti-mouse, anti-goat or anti-rabbit IgGs 
(Nordic Immunology; 1:3,000) and Biotin-SP anti-rat IgG 
(712-065-153; 1:500) from Jackson ImmunoResearch Inc. 
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were used as secondary antibodies. For the determination 
of protein carbonylation, the Oxyblot Oxidized Protein 
Detection kit (Chemicon International Inc.) was used. The 
blots were revealed using the ECL® reagent (Amersham 
Pharmacia Biotech). The intensity of the bands was 
quantified using a Kodak DC120 digital camera and the 
Kodak 1D Analysis Software.
Mitochondrial studies
Mitochondrial respiration was measured with the 
use of a Clark-type electrode [8]. The spectrophotometric 
determination of the activity of OXPHOS complexes 
was also carried out [55]. For Blue native (BN)-PAGE, 
Clear native (CN)-PAGE and In-gel activities, liver 
mitochondria were solubilized at the indicated digitonin/
protein ratios [56]. 
Reverse phase-liquid chromatography RP-LC-
MS/MS analysis (Dynamic Exclusion Mode)
After drying, gel bands from BN-PAGE were 
digested in situ with 12.5 ng/μl of trypsin (Promega) 
in 50 mM ammonium bicarbonate pH 8.8. Digestion 
was stopped by the addition of 1% trifluoracetic acid. 
Supernatants were dried down and then desalted onto 
ZipTip C18 Pipette tips (Millipore). The desalted protein 
digest was dried, resuspended in 10 µl of 0.1% formic 
acid and analyzed by RP-LC-MS/MS in an Easy-nLC II 
system coupled to an ion trap LTQ-Orbitrap-Velos-Pro 
mass spectrometer (Thermo Fischer Scientific, Bremen, 
Germany). The peptides were concentrated (on-line) 
by reverse phase chromatography using a 0.1mm×20 
mm precolumn Acclaim PepMap C18, 5 µm, 100 A 
(Thermo Fischer Scientific), and then separated using a 
0.075mm x 150 mm column Acclaim PepMap C18, 3 
µm, 100 A (Thermo Fischer Scientific) operating at 0.3 
μl/min. Peptides were eluted using a 90-min gradient 
from 5 to 40% solvent B (solvent A: 0.1% formic acid 
in water, solvent B: 0.1% formic acid, 80% acetonitrile 
in water). ESI ionization was done using a Nano-bore 
emitters Stainless Steel ID 30 μm (Proxeon) interface. 
The Orbitrap resolution was set at 30,000. Peptides were 
detected in survey scans from 400 to 1600 amu (1 μscan), 
followed by fifteen data dependent MS/MS scans (Top 
15), using an isolation width of 2µ (in mass-to-charge 
ratio units), normalized collision energy of 35%, and 
dynamic exclusion applied during 30 seconds periods. 
Peptide identification from raw data was carried out 
using the SEQUEST algorithm (Proteome Discoverer 
1.3, Thermo Scientific). Database search was performed 
against uniprot-mus.fasta. The following constraints were 
used for the searches: tryptic cleavage after Arg and Lys, 
up to two missed cleavage sites, and tolerances of 10 ppm 
for precursor ions and 0.8 Da for MS/MS fragment ions 
and the searches were performed allowing optional Met 
oxidation and Cys carbamidomethylation. Search against 
decoy database (integrated decoy approach) using false 
discovery rate (FDR) < 0.01.
Carcinogenesis
For an exploratory experiment of DEN-induced 
carcinogenesis two-week old control and Tet-Off T/H male 
mice received or not a single i.p. injection of DEN (25 mg/
kg bw) [23] and the animals were sacrificed at week 44. 
In the main experiment, two-week old control (n=35) and 
Tet-Off T/H (n=35) mice received or not an i.p. injection 
of DEN (0.33 mmol/kg bw) once weekly for a total of 
26 weeks [24]. Liver glutamate/pyruvate transaminase 
(GPT) was evaluated every 2 weeks using the Reflotron 
plus analyzer (Roche Diagnostics, Penzberg, Germany). 
Mice were sacrificed at week 29. 
Hepatotoxicity
Six month old control (n=8) and Tet-Off T/H (n=8) 
mice were used to induce hepatotoxicity. The animals 
were fasted for 14 hours and then received a single i.p. 
injection of APAP (300 mg/kg; Sigma Aldrich). Eight 
hours after the injection mice were sacrificed. 
Immunohistochemistry and immunofluorescence 
microscopy
The peroxidase based EnVisionTM FLEX Mini 
kit High pH (Dako Cytomation) and VECTASTAIN 
ABC kit (Vector Laboratories, Inc.) were used for 
immunohistochemistry using primary antibodies listed 
in Western blotting, antibodies and protein carbonylation 
section. The TUNEL kit (Roche) and anti-activated 
caspase 3 (1:250) were used to assess the rate of cell 
death. Secondary Cy-3/Cy-5-conjugated antibodies were 
used (Millipore Bioscience Research Reagents). Cellular 
fluorescence was analyzed by confocal microscopy. 
Electron microscopy
Liver slices were fixed and embedded in Epon 
(TAAB 812 resin; TAAB Laboratories Equipment, 
Aldermaston, Berks, UK). Ultrathin sections were stained 
and processed for electron microscopy as described [26]. 
Quantitative RT-PCR analysis
RNA samples were extracted using the RNAeasy 
mini kit (QIAGEN). Reverse transcription (RT) 
reactions were performed using 1μg of total RNA 
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and the High Capacity Reverse Transcription Kit 
(Applied Biosystems) with random primers. Primers 
were designed with Probe Finder Software (Roche 
Applied Science). The primers used were: m-IF1-F: 
agaagctggtggagccttc, m-IF1-R: ggcagccagctgttctttag; m-β-
F1-ATPase-F: ggcacaatgcaggaaagg, m-β-F1-ATPase-R: 
tcagcaggcacatagatagcc; m-Hsp60-F: tcttcaggttgtggcagtca, 
m-Hsp60-R: cccctcttctccaaacactg; m-GAPDH-F: 
agcttgtcatcaacgggaag, m-GAPDH-R: tttgatgttagtggggtctcg; 
m-PGC1α-F: gaaagggccaaacagagaga, m-PGC1α-R: 
gtaaatcacacggcgctctt; m-β-actin-F: ctaaggccaaccgtgaaaag, 
m-β-actin-R: accagaggcatacagggaca; h-IF1-F: 
gggccttcggaaagagag, h-IF1-R: ttcaaagctgccagttgttc. 
Real-time PCR was performed using Power Sybr Green 
PCR Master Mix (Bio-Rad) and an ABI PRISM 7900 
SDS thermocycler (Applied Biosystems). The relative 
expression of the mRNAs was determined using the 
comparative ΔΔCt method with β-actin as control and 
relative to the normal tissues. 
Determination of mitochondrial DNA (mtDNA) 
copy number
DNA (nDNA+mtDNA) was extracted using 
DNeasy Blood & Tissue Kit from Qiagen. Quantification 
of mtDNA (mtDNA/nDNA) was performed by qPCR 
in the ABI PRISM 7900HT SDS thermocycler (Applied 
Biosystems, Singapore) using 6 ng of DNA, 0.25 μM 
of primers and the Power Sybr Green PCR Master Mix 
(Bio-Rad). The nuclear ATPIF1 and the mitochondrial 
12S rRNA encoded genes were chosen to determine 
the ratio of mtDNA to nDNA. The primers used 
were: m-12S-F: cctcttagggttggtaaatttcg, m-12S-R: 
cgaagataattagtttgggttaatcg; m-IF1-F: agaagctggtggagccttc, 
m-IF1-R: ggcagccagctgttctttag. The relative mtDNA copy 
number was calculated using the ΔΔCt method and the 
12S/IF1 ratio used to compare the samples.
Swelling and Ca2+ uptake in isolated mitochondria
The calcium retention capacity (CRC) of isolated 
mitochondria was measured with the Ca2+-sensitive 
fluorescent probe Calcium-Green 5N (0.1 μM, excitation 
506 nm, emission 532 nm) as previously described 
[57], using an Aminco-Bowman II fluorimeter (SLM/
Aminco, Urbana, IL, USA). Mitochondrial swelling was 
measured by monitoring the decrease in absorbance of the 
suspension at 540 nm [58], using a Nicolet Evolution 300 
spectrophotometer (Thermo Scientific, Warrington, UK). 
All experiments were carried out at 37ºC in the presence 
of 1 mM MgCl2, respiratory substrates (5 mM succinate 
+ 2 μM rotenone) and in the presence or absence of 1 
mM ATP-Mg or 5 µM CsA. After 3-5 min of incubation, 
mitochondria were challenged with subsequent 2.5-10 
nmol CaCl2 additions as indicated in the figure legends, 
and Ca2+ uptake into mitochondria was measured as 
a decrease in fluorescence. For swelling assays, the 
absorbance at 540 nm of mitochondria was monitored 
through sequential additions of 100-500 nmol CaCl2. 
Statistical analysis
Statistical analyses were performed using a two-
tailed Student’s t-test. ANOVA with post hoc Dunnett’s 
test were used for multiple comparisons to the control, 
using the SPSS 17.0 software package. The results shown 
are means ± SEM. A p < 0.05 was considered statistically 
significant.
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